Reflux Clinical Trial
Official title:
The Role of Laryngopharyngeal Reflux in IPF
NCT number | NCT03418350 |
Other study ID # | HS-3130 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 1, 2018 |
Est. completion date | December 2025 |
The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 95 Years |
Eligibility | Inclusion Criteria: - Diagnosis of IPF - Age 40-95 - Able to read, speak, and understand English - If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent. Exclusion Criteria: - Patients who do not meet all inclusion criteria - Pregnant females |
Country | Name | City | State |
---|---|---|---|
United States | National Jewish Health | Denver | Colorado |
Lead Sponsor | Collaborator |
---|---|
National Jewish Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The supraglottic index (SGI) quantifies laryngopharyngeal reflux (LPF) and is associated with severity of pulmonary fibrosis. | Correlation between the supraglottic index and forced vital capacity. The supraglottic index is an index derived by assigning scores for edema and erythema of five supraglottic structures (epiglottis, false cords, arytenoids, posterior commissure, piriform recess) as viewed through a fiber-optic scope. Scores range from 0-22, with higher scores indicating more severe LPR. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01406210 -
RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol
|
N/A | |
Completed |
NCT01263626 -
Cough Monitoring Study
|
N/A | |
Completed |
NCT01154634 -
Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects
|
Phase 2 | |
Recruiting |
NCT05629143 -
Primary carE PPi dEprescRibing Trial
|
Phase 4 | |
Recruiting |
NCT05899491 -
Role of ARMA in Selective Subset of Refractory GERD Patients.
|
N/A | |
Active, not recruiting |
NCT02001727 -
HEP-FYN 12-Years Follow-up
|
N/A | |
Completed |
NCT00863161 -
Renal Impairment Study
|
Phase 1 | |
Active, not recruiting |
NCT00161096 -
On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication
|
Phase 3 | |
Not yet recruiting |
NCT05162079 -
Protocol for the ESREFLUJO Study: Epidemiological Study of Heartburn and Gastroesophageal Reflux in Community Pharmacy
|
||
Completed |
NCT00519441 -
Do Patients Who Have Had Surgery for Achalasia Suffer From Reflux
|
N/A | |
Completed |
NCT00175045 -
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
|
Phase 2 | |
Terminated |
NCT04006002 -
Mechanism of Weight Loss After Endoscopic and Laparoscopic Sleeve Procedures
|
||
Completed |
NCT02048449 -
Inter-rater Reliability of the Reflux Finding Score Among Gastroenterologists
|
N/A | |
Completed |
NCT00842387 -
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
|
N/A | |
Unknown status |
NCT00216788 -
The Effect of Nexium on Transmucosal Esophageal Leak
|
Phase 1 | |
Completed |
NCT01509352 -
Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication
|
N/A | |
Completed |
NCT04329000 -
On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.
|
N/A | |
Enrolling by invitation |
NCT05041608 -
Endoscopic Surgery for Gastrointestinal Disorders: A Multicenter Registry Study
|
||
Completed |
NCT02226484 -
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
|
Phase 1 | |
Completed |
NCT00687245 -
Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
|
Phase 1 |